NUVL
HEALTHCARENuvalent Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving NUVL Today?
No stock-specific AI insight has been generated for NUVL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$104.26
Fundamentals
Trading
NUVL News
21 articles- Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLCYahoo Finance·May 1, 2026
- Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformYahoo Finance·Apr 30, 2026
- Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial DataYahoo Finance·Apr 24, 2026
- Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual MeetingYahoo Finance·Apr 21, 2026
- New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026Yahoo Finance·Apr 17, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLCYahoo Finance·Apr 7, 2026
- Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?Motley Fool·Mar 22, 2026
- FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL)Yahoo Finance·Mar 19, 2026
- Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% RallyMotley Fool·Mar 17, 2026
- This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA DecisionMotley Fool·Mar 13, 2026
- Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugMotley Fool·Mar 13, 2026
- Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its PipelineMotley Fool·Mar 13, 2026
- Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf RegistrationYahoo Finance·Mar 11, 2026
- Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?Yahoo Finance·Feb 27, 2026
- Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Feb 26, 2026
- Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%Motley Fool·Feb 23, 2026
- Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 DataMotley Fool·Feb 19, 2026
- Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts AheadMotley Fool·Feb 19, 2026
All 21 articles loaded
Price Data
52-Week Range
$104.26
Fundamentals
Trading
About Nuvalent Inc - Class A
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company specializing in the development of targeted therapies for cancer patients with genetically defined diseases. Utilizing its proprietary drug discovery platform, Nuvalent aims to deliver innovative solutions that specifically address genetic mutations implicated in tumor growth, thereby enhancing patient outcomes while reducing side effects. With a robust pipeline of highly selective therapies, the company is strategically positioned to capitalize on emerging opportunities within the precision oncology market, emphasizing its commitment to transforming cancer treatment and significantly improving patient care in the oncology landscape.